Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAPIT: HDM SLIT-tablet in pediatric allergic asthma
NCT03654976Phase 3Completed
- Sponsor
- ALK-Abelló
- Start
- Feb 2018
- Primary completion
- May 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial of SQ SLIT-tablet in allergic asthma and allergic rhinitis (AR) (2 arms), sponsored by ALK-Abelló. Primary endpoint: Annualized Rate of Clinically Relevant Asthma Exacerbations at 20 months. Started Feb 2018; status: completed.
02
Drugs
SQ SLIT-tablet
03
Conditions
allergic asthmaallergic rhinitis (AR)
Beyond the preview
Go deeper on NCT03654976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03654976.